Gene expression profiling reveals complex changes in the olfactory bulbectomy model of depression after chronic treatment with antidepressants

Journal of Pharmacological Sciences

Volumn 108, Issue 3, 2008, Pages 320-334

  Takahashi, Kou ^a   Saitoh, Akiyoshi ^b   Yamada, Misa ^a   Maruyama, Yoshiaki ^a   Hirose, Noritaka ^b   Kamei, Junzo ^b   Yamada, Mitsuhiko ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Antidepressant; Delta opioid receptor; Gene expression; Model animal; Olfactory bulbectomy

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ACID ANHYDRIDE; ACYLTRANSFERASE; ANTIDEPRESSANT AGENT; DELTA OPIATE RECEPTOR; HYDROLASE; IMIPRAMINE; NEUROTRANSMITTER; PHOSPHORUS DERIVATIVE; PROTEIN SERINE THREONINE KINASE; ZINC ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DNA MICROARRAY; ENZYME ACTIVITY; FRONTAL CORTEX; GENE EXPRESSION PROFILING; MALE; NONHUMAN; OLFACTORY BULBECTOMY; PROTEIN MODIFICATION; RAT; REGULATORY MECHANISM;

EID: 56649116082     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08149FP     Document Type: Article

References (67)

1. Yamada M, Higuchi T. Functional genomics and depression research. Beyond the monoamine hypothesis. Eur Neuro psychopharmacol. 2002;12:235-244.
2. Wong ML, O'Kirwan F, Hannestad JP, Irizarry KJ, Elashoff D, Licinio J. St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol Psychiatry. 2004;9:237-251.
3. Conti B, Maier R, Barr AM, Morale MC, Lu X, Sanna PP, et al. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry. 2007;12:167-189.
4. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther. 1997;74:299-316.
5. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev. 2005;29:627-647.
6. Thorne BM, Rowles JS. Memory deficit in passive-avoidance learning in bulbectomized Long-Evans hooded rats. Physiol Behav. 1988;44:339-345.
7. Redmond AM, Kelly JP, Leonard BE. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav. 1997;58:355-359.
8. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther. 1999;289:926-935.
9. Ho YJ, Chen KH, Tai MY, Tsai YF. MK-801 suppresses muricidal behavior but not locomotion in olfactory bulbectomized rats: involvement of NMDA receptors. Pharmacol Biochem Behav. 2004;77:641-646.
10. Ho Y, Liu T, Tai M, Wen Z, Chow RS, Tsai Y, et al. Effects of olfactory bulbectomy on NMDA receptor density in the rat brain. Brain Res. 2001;900:214-218.
11. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A. Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci. 2002;22:10046-10052.
12. Hong KW, Lee WS, Rhim BY. Role of central alpha 2-adrenoceptors on the development of muricidal behavior in olfactory bulbectomized rats: effect of alpha 2-adrenoceptor antagonists. Physiol Behav. 1987;39:535-539.
13. Jesberger JA, Richardson JS. Animal models of depression: parallels and correlates to severe depression in humans. Biol Psychiatry. 1985;20:764-784.
14. Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behav Pharmacol. 2002;13:169-188.
15. van Riezen H, Leonard BE. Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther. 1990;47:21-34.
16. Cryan JF, McGrath C, Leonard BE, Norman TR. Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected? Eur J Pharmacol. 1998;352:23-28.
17. Redmond AM, Kelly JP, Leonard BE. The determination of the optimal dose of milnacipran in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav. 1999;62:619-623.
18. Mochizuki D, Tsujita R, Yamada S, Kawasaki K, Otsuka Y, Hashimoto S, et al. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl). 2002;162:323-332.
19. Wieronska JM, Papp M, Pilc A. Effects of anxiolytic drugs on some behavioral consequences in olfactory bulbectomized rats. Pol J Pharmacol. 2001;53:517-525.
20. Wieronska JM, Szewczyk B, Branski P, Palucha A, Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids. 2002;23:213-216.
21. Saitoh A, Yamada M, Yamada M, Takahashi K, Yamaguchi K, Murasawa H, et al. Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl] -(3-methoxyphenyl) methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model. Brain Res. 2008;1208:160-169.
22. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet. 2000;25:195-200.
23. Tejedor-Real P, Mico JA, Smadja C, Maldonado R, Roques BP, Gilbert-Rahola J. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol. 1998;354:1-7.
24. Baamonde A, Dauge V, Ruiz-Gayo M, Fulga IG, Turcaud S, Fournie-Zaluski MC, et al. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol. 1992;216:157-166.
25. Brady JV, Nauta WJ. Subcortical mechanisms in emotional behavior: the duration of affective changes following septal and habenular lesions in the albino rat. J Comp Physiol Psychol. 1955;48:412-420.
26. Shibata S, Nakanishi H, Watanabe S, Ueki S. Effects of chronic administration of antidepressants on mouse-killing behavior (muricide) in olfactory bulbectomized rats. Pharmacol Biochem Behav. 1984;21:225-230.
27. Yamada M, Iwabuchi T, Takahashi K, Kurahashi C, Ohata H, Honda K, et al. Identification and expression of frizzled-3 protein in rat frontal cortex after antidepressant and electroconvulsive treatment. J Pharmacol Sci. 2005;99:239-246.
28. Hubbell E, Liu WM, Mei R. Robust estimators for expression analysis. Bioinformatics. 2002;18:1585-1592.
29. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3.
30. Saitoh A, Yamaguchi K, Tatsumi Y, Murasawa H, Nakatani A, Hirose N, et al. Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats. Psychopharmacology (Berl). 2007;191:857-865.
31. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. J Neurosci. 1992;12:3628-3641.
32. Gunther EC, Stone DJ, Gerwien RW, Bento P, Heyes MP. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc Natl Acad Sci U S A. 2003;100:9608-9613.
33. Tan PK, Downey TJ, Spitznagel EL Jr, Xu P, Fu D, Dimitrov DS, et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res. 2003;31:5676-5684.
34. Yauk CL, Berndt ML, Williams A, Douglas GR. Comprehensive comparison of six microarray technologies. Nucleic Acids Res. 2004;32:e124.
35. Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods. 2005;2:351-356.
36. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, et al. Multiple-laboratory comparison of microarray platforms. Nat Methods. 2005;2:345-350.
37. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. Nat Methods. 2005;2:337-344.
38. Sherlock G. Of fish and chips. Nat Methods. 2005;2:329-330.
39. Maes M, De Vos N, Demedts P, Wauters A, Neels H. Lower serum zinc in major depression in relation to changes in serum acute phase proteins. J Affect Disord. 1999;56:189-194.
40. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry. 1997;42:349-358.
41. Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol. 2003;55:1143-1147.
42. Kroczka B, Branski P, Palucha A, Pilc A, Nowak G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull. 2001;55:297-300.
43. Szewczyk B, Branski P, Wieronska JM, Palucha A, Pilc A, Nowak G. Interaction of zinc with antidepressants in the forced swimming test in mice. Pol J Pharmacol. 2002;54:681-685.
44. Rosa AO, Lin J, Calixto JB, Santos AR, Rodrigues AL. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res. 2003;144:87-93.
45. Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull. 2003;61:159-164.
46. Nowak G, Szewczyk B, Pilc A. Zinc and depression. An update. Pharmacol Rep. 2005;57:713-718.
47. Cieslik K, Klenk-Majewska B, Danilczuk Z, Wrobel A, Lupina T, Ossowska G. Influence of zinc supplementation on imipramine effect in a chronic unpredictable stress (CUS) model in rats. Pharmacol Rep. 2007;59:46-52.
48. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry. 2003;54:840-846.
49. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a Pglycoprotein gene disruption. Neuropsychopharmacology. 2000;22:380-387.
50. Seelig A. A general pattern for substrate recognition by Pglycoprotein. Eur J Biochem. 1998;251:252-261.
51. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002;53:75-82.
52. Uz T, Ahmed R, Akhisaroglu M, Kurtuncu M, Imbesi M, Dirim Arslan A, et al. Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum. Neuroscience. 2005;134:1309-1316.
53. Uz T, Manev H. Chronic fluoxetine administration increases the serotonin N-acetyltransferase messenger RNA content in rat hippocampus. Biol Psychiatry. 1999;45:175-179.
54. Popsueva AE, Luchinskaya NN, Ludwig AV, Zinovjeva OY, Poteryaev DA, Feigelman MM, et al. Overexpression of camello, a member of a novel protein family, reduces blastomere adhesion and inhibits gastrulation in Xenopus laevis. Dev Biol. 2001;234:483-496.
55. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr. 1982;232:299-304.
56. Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol. 1995;5 Suppl:71-75.
57. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000;47:586-593.
58. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 2000;47:305-313.
59. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61:705-713.
60. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A. 1998;95:13290-13295.
61. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085-1098.
62. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545-553.
63. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A. 2005;102:15653-15658.
64. Michael-Titus AT, Bains S, Jeetle J, Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience. 2000;100:681-684.
65. Wang SJ, Su CF, Kuo YH. Fluoxetine depresses glutamate exocytosis in the rat cerebrocortical nerve terminals (synaptosomes) via inhibition of P/Q-type Ca2+ channels. Synapse. 2003;48:170-177.
66. Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci. 2005;25:3270-3279.
67. Takahashi K, Yamada M, Ohata H, Momose K, Higuchi T, Honda K. Expression of Ndrg2 in the rat frontal cortex after antidepressant and electroconvulsive treatment. Int J Neuropsychopharmacol. 2005;8:381-389.